{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:05:10Z","timestamp":1781712310574,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Hum Behav"],"DOI":"10.1038\/s41562-025-02103-x","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:05:00Z","timestamp":1740391500000},"page":"665-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Shrinking the know\u2013do gap in psychedelic-assisted therapy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-6129","authenticated-orcid":false,"given":"Ginger E.","family":"Nicol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-989X","authenticated-orcid":false,"given":"Danielle R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-4141","authenticated-orcid":false,"given":"Leopoldo J.","family":"Cabassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","volume":"10","author":"AA Feduccia","year":"2019","unstructured":"Feduccia, A. A. et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front. Psychiatry 10, 650 (2019).","journal-title":"Front. Psychiatry"},{"key":"2103_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109610","volume":"236","author":"DJ Heal","year":"2023","unstructured":"Heal, D. J., Smith, S. L., Belouin, S. J. & Henningfield, J. E. Psychedelics: threshold of a therapeutic revolution. Neuropharmacology 236, 109610 (2023).","journal-title":"Neuropharmacology"},{"key":"2103_CR3","unstructured":"MindMed, MindMed receives FDA breakthrough therapy designation and announces positive 12-week durability data from phase 2B study of MM120 for generalized anxiety disorder. ir.mindmed.co https:\/\/ir.mindmed.co\/news-events\/press-releases\/detail\/137\/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder (MindMed, 2024)."},{"key":"2103_CR4","unstructured":"APA. COVID-19 practitioner impact survey 2022. apa.org https:\/\/www.apa.org\/pubs\/reports\/practitioner\/2022-covid-psychologist-workload (American Psychological Association, 2022)."},{"key":"2103_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1186541","volume":"14","author":"SM Vi\u00f1a","year":"2023","unstructured":"Vi\u00f1a, S. M. & Stephens, A. L. Psychedelics and workplace harm. Front. Psychiatry 14, 1186541 (2023).","journal-title":"Front. Psychiatry"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/0269881117714049","volume":"31","author":"M Forstmann","year":"2017","unstructured":"Forstmann, M. & Sagioglou, C. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. J. Psychopharmacol. 31, 975\u2013988 (2017).","journal-title":"J. Psychopharmacol."},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/02698811221146356","volume":"37","author":"M Forstmann","year":"2023","unstructured":"Forstmann, M. et al. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. J. Psychopharmacol. 37, 93\u2013106 (2023).","journal-title":"J. Psychopharmacol."},{"key":"2103_CR8","doi-asserted-by":"crossref","unstructured":"Reardon, S. FDA rejects ecstasy as a therapy: what\u2019s next for psychedelics? Nature NEWS https:\/\/www.nature.com\/articles\/d41586-024-02597-x (13 August 2024).","DOI":"10.1038\/d41586-024-02597-x"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat. Med. 29, 2473\u20132480 (2023).","journal-title":"Nat. Med."},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","volume":"181","author":"GM Goodwin","year":"2024","unstructured":"Goodwin, G. M., Malievskaia, E., Fonzo, G. A. & Nemeroff, C. B. Must psilocybin always \u2018assist psychotherapy\u2019? Am. J. Psychiatry. 181, 20\u201325 (2024).","journal-title":"Am. J. Psychiatry."},{"key":"2103_CR11","unstructured":"Psychedelic Drugs: Considerations for Clinical Investigations (United States Food and Drug Administration, 2023)."},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"e2414650","DOI":"10.1001\/jamanetworkopen.2024.14650","volume":"7","author":"AL McGuire","year":"2024","unstructured":"McGuire, A. L. et al. Developing an ethics and policy framework for psychedelic clinical care: a consensus statement. JAMA Netw. Open 7, e2414650 (2024).","journal-title":"JAMA Netw. Open"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/add.16575","volume":"120","author":"CM Andrews","year":"2025","unstructured":"Andrews, C. M., Hall, W., Humphreys, K. & Marsden, J. Crafting effective regulatory policies for psychedelics: what can be learned from the case of cannabis?. Addiction 120, 201\u2013206 (2025).","journal-title":"Addiction"},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2023.1968","volume":"80","author":"ND Volkow","year":"2023","unstructured":"Volkow, N. D., Gordon, J. A. & Wargo, E. M. Psychedelics as therapeutics\u2014potential and challenges. JAMA Psychiatry. 80, 979\u2013980 (2023).","journal-title":"JAMA Psychiatry."},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41583-021-00465-5","volume":"22","author":"A Bara","year":"2021","unstructured":"Bara, A., Ferland, J. N., Rompala, G., Szutorisz, H. & Hurd, Y. L. Cannabis and synaptic reprogramming of the developing brain. Nat. Rev. Neurosci. 22, 423\u2013438 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1161\/STR.0000000000000396","volume":"53","author":"FD Testai","year":"2022","unstructured":"Testai, F. D. et al. Use of marijuana: effect on brain health: a scientific statement from the American Heart Association. Stroke 53, e176\u2013e187 (2022).","journal-title":"Stroke"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","volume":"15","author":"P Pacher","year":"2018","unstructured":"Pacher, P., Steffens, S., Hask\u00f3, G., Schindler, T. H. & Kunos, G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad and the ugly. Nat. Rev. Cardiol. 15, 151\u2013166 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/can.2023.0056","volume":"9","author":"AC Fernandez","year":"2024","unstructured":"Fernandez, A. C. et al. Prevalence and frequency of cannabis use among adults ages 50-80 in the United States. Cannabis Cannabinoid Res 9, 59\u201364 (2024).","journal-title":"Cannabis Cannabinoid Res"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel, J. S., Daily, J. E., Perry, D. A. & Nicol, G. E. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 80, 77\u201383 (2023).","journal-title":"JAMA Psychiatry."},{"key":"2103_CR20","unstructured":"National Council for Mental Wellbeing. New study: behavioral health workforce shortage will negatively impact society. thenationalcouncil.org https:\/\/www.thenationalcouncil.org\/news\/help-wanted\/ (25 April 2023)."},{"key":"2103_CR21","unstructured":"The economics of administration action on student debt. whitehouse.gov https:\/\/www.whitehouse.gov\/cea\/written-materials\/2024\/04\/08\/the-economics-of-administration-action-on-student-debt\/ (The White House, 2024)."},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/psymed.2022.0017","volume":"1","author":"MM Pleet","year":"2023","unstructured":"Pleet, M. M., White, J., Zamaria, J. A. & Yehuda, R. Reducing the harms of nonclinical psychedelics use through a peer-support telephone helpline. Psychedelic Med. (New Rochelle) 1, 69\u201373 (2023).","journal-title":"Psychedelic Med."},{"key":"2103_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","volume":"100","author":"BG Hearn","year":"2022","unstructured":"Hearn, B. G., Brubaker, M. D. & Richardson, G. Counselors\u2019 attitudes toward psychedelics and their use in therapy. J. Couns. Dev. 100, 364\u2013373 (2022).","journal-title":"J. Couns. Dev."},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/cpp.2880","volume":"30","author":"A Kucsera","year":"2023","unstructured":"Kucsera, A., Suppes, T. & Haug, N. A. Psychologists\u2019 and psychotherapists\u2019 knowledge, attitudes and clinical practices regarding the therapeutic use of psychedelics. Clin. Psychol. Psychotherapy 30, 1369\u20131379 (2023).","journal-title":"Clin. Psychol. Psychotherapy"},{"key":"2103_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.586682","volume":"12","author":"SJ Tai","year":"2021","unstructured":"Tai, S. J. et al. Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. Front. Psychiatry 12, 586682 (2021).","journal-title":"Front. Psychiatry"},{"key":"2103_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.866018","volume":"13","author":"W Brennan","year":"2022","unstructured":"Brennan, W. & Belser, A. B. Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a transdiagnostic, trans-drug model. Front. Psychol. 13, 866018 (2022).","journal-title":"Front. Psychol."},{"key":"2103_CR27","unstructured":"Columbia School of Social Work. Psychedelic therapy training program online. columbia.edu https:\/\/pttp.socialwork.columbia.edu\/ (Columbia Univ., accessed 24 June 2024)."},{"key":"2103_CR28","unstructured":"Center for Mental Health Services Research, Washington University. Psychedelic-assisted therapies learning community (PAT LC) online. wustl.edu https:\/\/cmhsr.wustl.edu\/research-projects\/psychedelic-assisted-therapies-learning-community-pat-lc\/?_ga=2.253513345.980339201.1719325568-530958589.1639675267 (Brown School at Washington Univ. in St Louis, accessed 24 June 2024)."},{"key":"2103_CR29","unstructured":"Department of Health and Human Services. Dissemination and implementation research in health (R01) NIH funding opportunity: PAR-19-274. nih.gov https:\/\/grants.nih.gov\/grants\/guide\/pa-files\/PAR-19-274.html (NIH, 2018)."},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1748-5908-9-45","volume":"9","author":"GA Aarons","year":"2014","unstructured":"Aarons, G. A., Ehrhart, M. G. & Farahnak, L. R. The Implementation Leadership Scale (ILS): development of a brief measure of unit level implementation leadership. Implement. Sci. 9, 45 (2014).","journal-title":"Implement. Sci."},{"key":"2103_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1748-5908-6-80","volume":"6","author":"LJ Cabassa","year":"2011","unstructured":"Cabassa, L. J., Druss, B., Wang, Y. & Lewis-Fern\u00e1ndez, R. Collaborative planning approach to inform the implementation of a healthcare manager intervention for Hispanics with serious mental illness: a study protocol. Implement. Sci. 6, 80 (2011).","journal-title":"Implement. Sci."},{"key":"2103_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13012-014-0178-9","volume":"9","author":"LJ Cabassa","year":"2014","unstructured":"Cabassa, L. J. et al. Using the collaborative intervention planning framework to adapt a health-care manager intervention to a new population and provider group to improve the health of people with serious mental illness. Implement. Sci. 9, 178 (2014).","journal-title":"Implement. Sci."},{"key":"2103_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.06.042","volume":"283","author":"JE Kirchner","year":"2020","unstructured":"Kirchner, J. E., Smith, J. L., Powell, B. J., Waltz, T. J. & Proctor, E. K. Getting a clinical innovation into practice: an introduction to implementation strategies. Psychiatry Res. 283, 112467 (2020).","journal-title":"Psychiatry Res."},{"key":"2103_CR34","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s10488-022-01218-x","volume":"49","author":"HE Frank","year":"2022","unstructured":"Frank, H. E., Kemp, J., Benito, K. G. & Freeman, J. B. Precision implementation: an approach to mechanism testing in implementation research. Adm. Policy Ment. Health 49, 1084\u20131094 (2022).","journal-title":"Adm. Policy Ment. Health"},{"key":"2103_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-021-01137-9","volume":"16","author":"AR Dopp","year":"2021","unstructured":"Dopp, A. R. et al. Translating economic evaluations into financing strategies for implementing evidence-based practices. Implement. Sci. 16, 66 (2021).","journal-title":"Implement. Sci."},{"key":"2103_CR36","unstructured":"Guise J. M. et al. Systematic Reviews of Complex Multicomponent Health Care Interventions (US Agency for Healthcare Research and Quality, 2014)."},{"key":"2103_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"2103_CR38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323, 844\u2013853 (2020).","journal-title":"JAMA"},{"key":"2103_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","volume":"632","author":"JS Siegel","year":"2024","unstructured":"Siegel, J. S. et al. Psilocybin desynchronizes the human brain. Nature 632, 131\u2013138 (2024).","journal-title":"Nature"},{"key":"2103_CR40","doi-asserted-by":"publisher","first-page":"e18609","DOI":"10.2196\/18609","volume":"8","author":"GE Nicol","year":"2020","unstructured":"Nicol, G. E. et al. A smartphone-based technique to detect dynamic user preferences for tailoring behavioral interventions: observational utility study of ecological daily needs assessment. JMIR Mhealth Uhealth 8, e18609 (2020).","journal-title":"JMIR Mhealth Uhealth"},{"key":"2103_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1126\/science.abn0184","volume":"374","author":"EK Proctor","year":"2021","unstructured":"Proctor, E. K. & Geng, E. A new lane for science. Science 374, 659 (2021).","journal-title":"Science"},{"key":"2103_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ps.201100430","volume":"63","author":"GB Teague","year":"2012","unstructured":"Teague, G. B., Mueser, K. T. & Rapp, C. A. Advances in fidelity measurement for mental health services research: four measures. Psychiatr. Serv. 63, 765\u2013771 (2012).","journal-title":"Psychiatr. Serv."},{"key":"2103_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1034-z","volume":"16","author":"RS Beidas","year":"2016","unstructured":"Beidas, R. S. et al. A randomized trial to identify accurate and cost-effective fidelity measurement methods for cognitive-behavioral therapy: project FACTS study protocol. BMC Psychiatry. 16, 323 (2016).","journal-title":"BMC Psychiatry."},{"key":"2103_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-clinpsy-032511-143152","volume":"8","author":"H Lei","year":"2012","unstructured":"Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D. & Murphy, S. A. A \u2018SMART\u2019 design for building individualized treatment sequences. Annu. Rev. Clin. Psychol. 8, 21\u201348 (2012).","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"2103_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06808-3","volume":"21","author":"L Huynh","year":"2021","unstructured":"Huynh, L., Toyserkani, G. A. & Morrato, E. H. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018). BMC Health Serv. Res. 21, 779 (2021).","journal-title":"BMC Health Serv. Res."},{"key":"2103_CR46","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1055\/s-0042-1758838","volume":"13","author":"S Tajchman","year":"2022","unstructured":"Tajchman, S. et al. Implementation and use of risk evaluation and mitigation strategies programs in practice: a scoping review of the literature. Appl. Clin. Inform. 13, 1151\u20131160 (2022).","journal-title":"Appl. Clin. Inform."},{"key":"2103_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12961-024-01102-0","volume":"22","author":"MY Smith","year":"2024","unstructured":"Smith, M. Y., Gaglio, B. & Anatchkova, M. The use of implementation science theories, models, and frameworks in implementation research for medicinal products: a scoping review. Health Res. Policy Syst. 22, 17 (2024).","journal-title":"Health Res. Policy Syst."},{"key":"2103_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/cts.12495","volume":"11","author":"DA Luke","year":"2018","unstructured":"Luke, D. A. et al. The Translational Science Benefits Model: a new framework for assessing the health and societal benefits of clinical and translational sciences. Clin. Transl. Sci. 11, 77\u201384 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"2103_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1017\/cts.2019.386","volume":"3","author":"AT Ramsey","year":"2019","unstructured":"Ramsey, A. T. et al. Designing for Accelerated Translation (DART) of emerging innovations in health. J. Clin. Transl. Sci. 3, 53\u201358 (2019).","journal-title":"J. Clin. Transl. Sci."},{"key":"2103_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s43477-022-00045-4","volume":"2","author":"E Proctor","year":"2022","unstructured":"Proctor, E. et al. FAST: a framework to assess speed of translation of health innovations to practice and policy. Glob. Implement. Res. Appl. 2, 107\u2013119 (2022).","journal-title":"Glob. Implement. Res. Appl."},{"key":"2103_CR51","first-page":"18","volume":"37","author":"D Sarewitz","year":"2020","unstructured":"Sarewitz, D. \u2018Unknown knowns\u2019. Issues Sci. Technol. 37, 18\u201319 (2020).","journal-title":"Issues Sci. Technol."},{"key":"2103_CR52","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3390\/ijerph17103457","volume":"17","author":"S Gerritsen","year":"2020","unstructured":"Gerritsen, S. et al. Community group model building as a method for engaging participants and mobilising action in public health. Int. J. Environ. Res. Public Health 17, 3457 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"2103_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jagp.2022.08.007","volume":"31","author":"CB Johnston","year":"2023","unstructured":"Johnston, C. B., Mangini, M., Grob, C. & Anderson, B. The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns. Am. J. Geriatr. Psychiatry 31, 44\u201353 (2023).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"2103_CR54","doi-asserted-by":"publisher","unstructured":"Kettner, H., Roseman, L., Gazzaley, A., Carhart-Harris, R. & Pasquini, L. Improvements in well-being following naturalistic psychedelic use and underlying mechanisms of change in older adults: a prospective cohort study. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-3977169\/v1 (2024).","DOI":"10.21203\/rs.3.rs-3977169\/v1"}],"container-title":["Nature Human Behaviour"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41562-025-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41562-025-02103-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41562-025-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:03:38Z","timestamp":1745445818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41562-025-02103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1038\/s41562-025-02103-x","relation":{},"ISSN":["2397-3374"],"issn-type":[{"value":"2397-3374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.E.N. has received salary support from institutional grants supported by the National Center for Translational Sciences (NCATS) and the National Institute of Digestive and Diabetes and Kidney Diseases (NIDDK), research support from the National Institute of Mental Health (NIMH), the Health Resources and Services Administration (HRSA), the Patient Centered Outcomes Research Institute (PCORI), the Barnes Jewish Hospital Foundation and the Institute for Clinical Translational Sciences, the Taylor Family Institute for Innovative Psychiatric Research, the Mallinckrodt Institute of Radiology, the McDonnell Center for Systems Neuroscience and the Center for Holistic Interdisciplinary Research in Psychedelics (CHIRP), funded by a Transcend Initiative Grant through the Here & Next Research Grants programme at Washington University. She has served as a co-investigator or principal investigator for studies funded by COMPASS Pathways, LB Pharmaceuticals, Inc., Usona Institute and Alkermes, Inc., and has received personal fees as a consultant from Carelon, Novartis and Alkermes, Inc. D.R.A. has received grant support from the NIMH (T32MH019960). E.J.L. has received grant support from Fast grants and Jansen, has consulting relationships with Pritikin ICR, Boehringer Ingelheim, Merck, IngenioRX and Prodeo and a patent pending for the use of fluvoxamine for COVID-19. L.J.C. has received research support from NIMH (T32MH019960), the Washington University in St Louis Institute for Public Health and the Center for Dissemination and Implementation (D&I) and the Center for Mental Health Services Research in the Brown School at Washington University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}